Discover how FF-10101, a novel CSF1R inhibitor with unique covalent binding, reprograms tumor-associated macrophages to create an anti-tumor immune environment and enhances cancer immunotherapy.
Explore the groundbreaking Phase I trial of hu3S193, a humanized monoclonal antibody targeting Lewis-Y antigen in epithelial cancers. Learn about its precision targeting, pharmacokinetics, and future therapeutic potential.